13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • NAPOLI 3

    Acronym: 

    NAPOLI 3

    ACTRN/NCT /ethics: 

    Scientific title: 

    An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas

    Summary of trial and patient characteristics

    Cancer Type Pancreas
    Trial Type Treatment
    Phase Phase III Tumour Stream Pancreas
    Age Range 18 years and older Cancer Stage Metastatic or Widespread, Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Pancreas
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Pancreas
    Cancer Stage Metastatic or Widespread, Locally Recurrent or Locally Advanced
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas

    Lay Summary

    An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    The Queen Elizabeth Hospital Pamela Cooper pamela.cooper@sa.gov.au 08 8222 6140 Dr Vy Broadbridge Not Yet Recruiting